Sentences with phrase «stock sharing program»

In the meantime, he's thankful his employer provides him with a defined benefit pension plan and the option to join a stock sharing program.

Not exact matches

«Sheetz shares its profits by giving quarterly bonuses to all eligible employees and by enrolling us into the employee stock ownership program.

In an open letter to Apple CEO Tim Cook, posted to Icahn's website Thursday, he outlined a share buyback program in which Apple would repurchase $ 150 billion of its own stock in order to improve company growth.

From the inception of our Stock Repurchase Program through April 27, 2018, we repurchased approximately 23.7 million shares of our common stock at an aggregate market value of approximately $ 1.5 bilStock Repurchase Program through April 27, 2018, we repurchased approximately 23.7 million shares of our common stock at an aggregate market value of approximately $ 1.5 bilstock at an aggregate market value of approximately $ 1.5 billion.

Citigroup was the highlight after hours, doubling its quarterly dividend to 32 cents per common share and announcing a common stock repurchase program of up to $ 15.6 billion.

In an interview, Rendle told Fortune the company is looking for its next big deal, even as he said VF would focus on building up its online and international businesses to spur growth, and touted a $ 5 billion share buyback program to boost the stock.

Employee stock - option programs are typically authorized by a company's board of directors (and have historically been approved by the shareholders) and give the company discretion to award options to employees equal to a certain percentage of the company's shares outstanding.

The company repurchased 1.6 million shares of common stock for $ 24.3 million during the first quarter under the company's $ 300 million share buyback program.

Since 2012, when the company launched the largest share repurchase program ever, Apple has returned a little more than $ 100 billion to shareholders in stock buybacks and dividends.

The company also approved a new $ 40 billion share buyback program, reaffirming it's on track to complete its current $ 40 billion stock repurchase program by December 31.

After one year of employment, ownership is awarded through the Employee Stock Ownership Program and employee - owners start sharing in company profits.

Early last year, Martin competed in Jet's «Insiders» referral program, ultimately spending about $ 18,000 to cinch himself the top prize of 100,000 shares of common stock.

These risks and uncertainties include: Gilead's ability to achieve its anticipated full year 2018 financial results; Gilead's ability to sustain growth in revenues for its antiviral and other programs; the risk that private and public payers may be reluctant to provide, or continue to provide, coverage or reimbursement for new products, including Vosevi, Yescarta, Epclusa, Harvoni, Genvoya, Odefsey, Descovy, Biktarvy and Vemlidy ®; austerity measures in European countries that may increase the amount of discount required on Gilead's products; an increase in discounts, chargebacks and rebates due to ongoing contracts and future negotiations with commercial and government payers; a larger than anticipated shift in payer mix to more highly discounted payer segments and geographic regions and decreases in treatment duration; availability of funding for state AIDS Drug Assistance Programs (ADAPs); continued fluctuations in ADAP purchases driven by federal and state grant cycles which may not mirror patient demand and may cause fluctuations in Gilead's earnings; market share and price erosion caused by the introduction of generic versions of Viread and Truvada, an uncertain global macroeconomic environment; and potential amendments to the Affordable Care Act or other government action that could have the effect of lowering prices or reducing the number of insured patients; the possibility of unfavorable results from clinical trials involving investigational compounds; Gilead's ability to initiate clinical trials in its currently anticipated timeframes; the levels of inventory held by wholesalers and retailers which may cause fluctuations in Gilead's earnings; Kite's ability to develop and commercialize cell therapies utilizing the zinc finger nuclease technology platform and realize the benefits of the Sangamo partnership; Gilead's ability to submit new drug applications for new product candidates in the timelines currently anticipated; Gilead's ability to receive regulatory approvals in a timely manner or at all, for new and current products, including Biktarvy; Gilead's ability to successfully commercialize its products, including Biktarvy; the risk that physicians and patients may not see advantages of these products over other therapies and may therefore be reluctant to prescribe the products; Gilead's ability to successfully develop its hematology / oncology and inflammation / respiratory programs; safety and efficacy data from clinical studies may not warrant further development of Gilead's product candidates, including GS - 9620 and Yescarta in combination with Pfizer's utomilumab; Gilead's ability to pay dividends or complete its share repurchase program due to changes in its stock price, corporate or other market conditions; fluctuations in the foreign exchange rate of the U.S. dollar that may cause an unfavorable foreign currency exchange impact on Gilead's future revenues and pre-tax earnings; and other risks identified from time to time in Gilead's reports filed with the U.S. Securities and Exchange Commission (tprograms; the risk that private and public payers may be reluctant to provide, or continue to provide, coverage or reimbursement for new products, including Vosevi, Yescarta, Epclusa, Harvoni, Genvoya, Odefsey, Descovy, Biktarvy and Vemlidy ®; austerity measures in European countries that may increase the amount of discount required on Gilead's products; an increase in discounts, chargebacks and rebates due to ongoing contracts and future negotiations with commercial and government payers; a larger than anticipated shift in payer mix to more highly discounted payer segments and geographic regions and decreases in treatment duration; availability of funding for state AIDS Drug Assistance Programs (ADAPs); continued fluctuations in ADAP purchases driven by federal and state grant cycles which may not mirror patient demand and may cause fluctuations in Gilead's earnings; market share and price erosion caused by the introduction of generic versions of Viread and Truvada, an uncertain global macroeconomic environment; and potential amendments to the Affordable Care Act or other government action that could have the effect of lowering prices or reducing the number of insured patients; the possibility of unfavorable results from clinical trials involving investigational compounds; Gilead's ability to initiate clinical trials in its currently anticipated timeframes; the levels of inventory held by wholesalers and retailers which may cause fluctuations in Gilead's earnings; Kite's ability to develop and commercialize cell therapies utilizing the zinc finger nuclease technology platform and realize the benefits of the Sangamo partnership; Gilead's ability to submit new drug applications for new product candidates in the timelines currently anticipated; Gilead's ability to receive regulatory approvals in a timely manner or at all, for new and current products, including Biktarvy; Gilead's ability to successfully commercialize its products, including Biktarvy; the risk that physicians and patients may not see advantages of these products over other therapies and may therefore be reluctant to prescribe the products; Gilead's ability to successfully develop its hematology / oncology and inflammation / respiratory programs; safety and efficacy data from clinical studies may not warrant further development of Gilead's product candidates, including GS - 9620 and Yescarta in combination with Pfizer's utomilumab; Gilead's ability to pay dividends or complete its share repurchase program due to changes in its stock price, corporate or other market conditions; fluctuations in the foreign exchange rate of the U.S. dollar that may cause an unfavorable foreign currency exchange impact on Gilead's future revenues and pre-tax earnings; and other risks identified from time to time in Gilead's reports filed with the U.S. Securities and Exchange Commission (tPrograms (ADAPs); continued fluctuations in ADAP purchases driven by federal and state grant cycles which may not mirror patient demand and may cause fluctuations in Gilead's earnings; market share and price erosion caused by the introduction of generic versions of Viread and Truvada, an uncertain global macroeconomic environment; and potential amendments to the Affordable Care Act or other government action that could have the effect of lowering prices or reducing the number of insured patients; the possibility of unfavorable results from clinical trials involving investigational compounds; Gilead's ability to initiate clinical trials in its currently anticipated timeframes; the levels of inventory held by wholesalers and retailers which may cause fluctuations in Gilead's earnings; Kite's ability to develop and commercialize cell therapies utilizing the zinc finger nuclease technology platform and realize the benefits of the Sangamo partnership; Gilead's ability to submit new drug applications for new product candidates in the timelines currently anticipated; Gilead's ability to receive regulatory approvals in a timely manner or at all, for new and current products, including Biktarvy; Gilead's ability to successfully commercialize its products, including Biktarvy; the risk that physicians and patients may not see advantages of these products over other therapies and may therefore be reluctant to prescribe the products; Gilead's ability to successfully develop its hematology / oncology and inflammation / respiratory programs; safety and efficacy data from clinical studies may not warrant further development of Gilead's product candidates, including GS - 9620 and Yescarta in combination with Pfizer's utomilumab; Gilead's ability to pay dividends or complete its share repurchase program due to changes in its stock price, corporate or other market conditions; fluctuations in the foreign exchange rate of the U.S. dollar that may cause an unfavorable foreign currency exchange impact on Gilead's future revenues and pre-tax earnings; and other risks identified from time to time in Gilead's reports filed with the U.S. Securities and Exchange Commission (tprograms; safety and efficacy data from clinical studies may not warrant further development of Gilead's product candidates, including GS - 9620 and Yescarta in combination with Pfizer's utomilumab; Gilead's ability to pay dividends or complete its share repurchase program due to changes in its stock price, corporate or other market conditions; fluctuations in the foreign exchange rate of the U.S. dollar that may cause an unfavorable foreign currency exchange impact on Gilead's future revenues and pre-tax earnings; and other risks identified from time to time in Gilead's reports filed with the U.S. Securities and Exchange Commission (the SEC).

By utilizing full shares, this program is typically less dilutive than stock options while providing alignment with stockholders.

For stockholders of record: The proxy card you received covers the number of shares to be voted in your account as of the record date, including any shares held for participants in the IBM Investor Services Program and Employees Stock Purchase Plans.

The structure of these employee stock guarantee programs also suggests that the banks that have lent money against shares pledged as collateral are likely to take much larger losses than they expect.

In August 2012, to create incentives for continued long - term success from the then - recently launched Model S program as well as from Tesla's then - planned Model X and Model 3 programs, and to further align executive compensation with increases in stockholder value, the Board granted to Mr. Musk a stock option award to purchase 5,274,901 shares of Tesla's common stock (the «2012 CEO Performance Award»), representing 5 % of Tesla's total issued and outstanding shares at the time of grant.

The board of directors of T. Rowe Price Group approved adding another 10 million shares to it stock repurchase plan, expanding that program to 21 million shares, the Baltimore - based money management firm announced Thursday.

The El Dorado, Arkansas - based company also said its board authorized a special dividend of $ 2.50 per share for a total payout of about $ 500 million, and a common stock buyback program of up to $ 1 billion.

If an award of stock options or stock appreciation rights expires or becomes unexercisable without having been exercised in full or is surrendered pursuant to an exchange program or shares issued through awards of restricted stock, restricted stock units, performance units, performance shares, or stock - settled performance awards are forfeited to us or

Apple's stock buyback program isn't just bigger than those of other companies, it's also better at doing what investors want share repurchases to do.

Between 1984 and 1993, Coca - Cola acquired 570 million shares of its own stock through its stock repurchase program, reducing the shares outstanding from 3.174 billion to 2.604 billion.

Country fund outflows of $ 21 billion are focused in a group of 10 locally - listed China A Shares funds, due to concerns over valuations and the impact of the Shanghai Hong Kong Stock Connect program on ETFs.

Announced a 5 million share increase to their buyback program, bringing their total authorized buyback plan to 10 million shares which will retire about 10 % of the company's outstanding stock if fully executed.

In addition, the company announced that its Board of Directors has authorized a share repurchase program under which the company may repurchase up to 3,500,000 shares of its outstanding common stock.

The company's board of directors has authorized the repurchase of an additional 2 million shares of its common stock, bringing the total share authorization under its share repurchase program to approximately 3.4 million shares.

Other than the underwriting discount described on the front cover of this prospectus, the underwriters will not be entitled to any commission with respect to shares of common stock sold pursuant to the directed share program.

If an Award expires or becomes unexercisable without having been exercised in full, is surrendered pursuant to an Exchange Program, or, with respect to Restricted Stock, Restricted Stock Units, Performance Units or Performance Shares, is forfeited to or repurchased by the Company due to failure to vest, the unpurchased Shares (or for Awards other than Options or Stock Appreciation Rights the forfeited or repurchased Shares), which were subject thereto will become available for future grant or sale under the Plan (unless the Plan has terminated).

HP repurchases shares of its stock under an ongoing program to manage the dilution created by shares issued under employee stock plans as well as to repurchase shares opportunistically.

A number of Chinese companies are trying to shore up their stock prices with programs that encourage employees to buy shares and ensuring them against losses.

Today more than 25 million American workers are part of some form of employee - ownership program, including an option to buy stock at a discount or receive part of their compensation in shares, says Corey Rosen, co-founder of the National Center for Employee Ownership.

• Equity and performance based plans (e.g., annual and long - term incentive plans, stock option, restricted stock, performance share and broad - based equity plans); • Executive plans (e.g., deferred compensation, supplemental retirement, severance and change - in - control plans); • Retirement plans (e.g., 401 (k) plans, traditional defined benefit pension plans and ESOPs); and • Health and welfare plans (including COBRA and HIPAA compliance), and other fringe benefit programs.

During fiscal 2014, the company repurchased 36.8 million shares as part of our stock repurchase program.

After the news of Apple's $ 100 billion share buyback program, Apple stock is up 4 percent

The reduction in outstanding shares resulting from the stock repurchase program increased fiscal 2014 EPS.

He also serves as Director of a national fellowship program based at Rutgers University that awards research fellowships to young and emerging researchers on employee stock ownership and profit sharing with over 120 fellows at colleges and universities and states throughout the U.S. and sponsors bi-annual research conferences on these issues.

Select Medical did not repurchase shares during the first quarter ended March 31, 2018 under its authorized $ 500.0 million stock repurchase program.

Yet, even that sum could be highly conservative because Harvard's numbers — released last week on its website — fails to include such things as performance bonuses, reimbursements, profit sharing, 401K matching programs, restricted stock or stock options.

Warren Buffett's conglomerate Berkshire Hathaway said it will launch a share buyback program, an extremely rare move from Buffett that comes after months of investor complaints that the stock was undervalued.

For private stock, you have to dig a little deeper to find someone willing to buy the shares, or let the company repurchase the shares from you in stock buyback program.

The stock market whiplash also poses a credibility problem for the Communist regime, particularly with regard to its economic and financial liberalization program, of which the progressive opening of the domestic share market was meant to be a part.

11-18-2005 2005 Drilling Program Completed on Caledonia's Mulonga Plain Joint Venture 11-14-2005 Caledonia Mining 3rd Quarter Results 2005 10-13-2005 Available online: Webcast of presentation to the Minesite Forum 10-11-2005 London: Presentation to the Minesite Forum 09-14-2005 Caledonia amends terms of share purchase warrants 09-13-2005 Caledonia and Motapa announce 11 drill targets at Mulonga Plain Kashiji Plain analytical results confirm possible local source 08-15-2005 Caledonia Mining signs a Memorandum of Understanding with a South African Black Economic Empowerment Consortium 08-12-2005 Caledonia Mining Second Quarter Results 2005 08-11-2005 Caledonia Mining Second Quarter Results Conference Call and Webcast 07-18-2005 Caledonia announces Summer Drilling Program on Kikerk Lake Property, Nunavut 06-22-2005 Caledonia Mining Corporation announces Admission to the AIM Market of the London Stock Exchange and # 1.57 million placing 06-13-2005 Caledonia Mining signs a Letter of Intent with a Cobalt Refinery to supply 3 % of total annual world production 05-16-2005 Caledonia Mining 1st Quarter Results 2005 05-06-2005 Caledonia Annual Meeting set for Tuesday May 10th 2005 05-05-2005 Caledonia Mining Granted Prospecting Right for Grasvally and Will Commence the Drilling Program by Mid May 2005 03-29-2005 Caledonia Mining 4th Quarter and 2004 Annual Results 03-23-2005 Caledonia Mining Fourth Quarter and Annual results Conference call & webcast 03-08-2005 Mulonga Plain JV Exploration Work Program Update 02-23-2005 Caledonia Mining Appoints New Chairman 01-31-2005 Caledonia updates diamond exploration results at Mulonga Plain joint venture in Zambia.

When a board of directors authorizes a share repurchase program, it typically states either the number of shares the company is interested in buying back or a dollar amount it will spend on its stock buyback.

Typically, when a company announced a stock buyback program, the prospect of repurchases boosts the share price.

Berkshire has an open - ended share repurchase program that authorizes management to repurchase shares if the stock price drops below a price - to - book ratio of 1.2 x.

Brosens estimates these program trading strategies have in aggregate a total stock market exposure north of $ 1 trillion dollars — a somewhat larger share than portfolio insurance back in 1987.

In what could be called the «ultimate stock buyback program,» TPL is using multiple income streams to eventually repurchase all of its outstanding shares.

Share Repurchase Program During the second quarter of 2014, the company repurchased 936,060 shares of its common stock at an average price of $ 55.56 per share for a total of approximately $ 52 milShare Repurchase Program During the second quarter of 2014, the company repurchased 936,060 shares of its common stock at an average price of $ 55.56 per share for a total of approximately $ 52 milshare for a total of approximately $ 52 million.

If you had used your $ 1.50 per share in cash dividends to buy more stock, you could have theoretically increased your total share ownership position by around 2 percent if you did it through a low - cost dividend reinvestment program or a broker that didn't charge for the service.

Through July 22, 2014, the company has repurchased a total of nearly 2.5 million shares of its common stock for a total of $ 134 million since the launch of the program on October 20, 2013.